**Name of Journal:** *World Journal of Gastrointestinal Surgery*

**Manuscript NO:** 39920

**Manuscript Type:** EDITORIAL

**Liver preservation prior to transplantation: Past, present, and future**

Chedid MF *et al*.Preservation of liver allograft

Marcio F Chedid, Marcelo A Pinto, Jose Felipe G Juchem, Tomaz J M Grezzana-Filho, Cleber R P Kruel

**Marcio F Chedid, Marcelo A Pinto, Jose Felipe G Juchem, Tomaz J M Grezzana-Filho, Cleber R P Kruel,** Liver Transplant and Hepatobiliary Surgery Unit, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul (UFRGS), Porto Alegre 90035-903, Brazil

**ORCID number:** Marcio F Chedid ([0000-0001-6182-6963](https://orcid.org/0000-0001-6182-6963)); Marcelo A Pinto (0000-0003-1833-2524); Jose Felipe G Juchem (0000-0002-2466-7788); Tomaz J M Grezzana-Filho (0000-0002-8597-4343); Cleber R P Kruel (0000-0001-5942-712X).

**Author contributions**: Chedid MF, Pinto MA, Juchem JFG, Grezzana-Filho TJM and Kruel CRP conceived the study and drafted the manuscript; all authors approved the final version of the article.

**Conflict-of-interest statement:** The authors have no conflict of interest to declare.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Corresponding author:** **Marcio F Chedid, MD, PhD, Professor, Surgeon,** Liver Transplant and Hepatobiliary Surgery Unit and Graduate Program in Surgical Sciences, Hospital de Clínicas de Porto Alegre, Federal University of Rio Grande do Sul (UFRGS), Porto Alegre 90035-903, Brazil. marciochedid@hotmail.com

**Telephone:** +55-51-997721980

**Received:** March 1, 2019

**Peer-review started:** March 4, 2019

**First decision:** March 19, 2019

**Revised:** March 19, 2019

**Accepted:** March 20, 2019

**Article in press:** March 20, 2019

**Published online:** March 27, 2019

**Abstract**

Since Dr. Thomas Starzl performed the first series of successful liver transplants (LTs), important advances have been made in immunosuppression, operative techniques, and postoperative care.In 1988, Belzer’s group reported the first successful LT using the University of Wisconsin preservation solution (UW). Since then, UW has replaced EuroCollins solution and allowed prolonged and safer preservation of liver, kidney, and pancreas allografts, thus contributing to the improvement of transplant outcomes. Although UW is still considered the standard of care in the United States and in several countries worldwide, a recent meta-analysis revealed similar LT outcomes among UW, Celsior solution, and the Institut Georges Lopez-1 preservation solution, which were slightly superior to those obtained with histidine-tryptophan-ketoglutarate preservation solution. Dynamic preservation has been recently developed, and liver allografts are preserved mainly through the following methods: hypothermic machine perfusion, normothermic machine perfusion, and subnormothermic machine perfusion. Their use has the potential advantage of improving clinical results in LT involving extended criteria donor allografts. Although associated with increased costs, techniques employing machine perfusion of liver allografts have been considered clinically feasible. This editorial focuses on recent advances and future perspectives in liver allograft preservation.

**Key words:** Liver transplantation; University of Wisconsin preservation solution; Institute Georges Lopez preservation solution; Celsior preservation solution; Histidine-tryptophan-ketoglutarate preservation solution; Dymamic preservation; Normothermic ischemia; Normothermic preservation; Hypotermic machine preservation; Static cold prreservation

**© The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip**: Important advances in immunosuppression, operative techniques, and postoperative care have been made in liver transplantation over time. The success of a transplant is largely dependent on adequate organ preservation. This editorial focuses on recent advances in the preservation of liver allografts.

Chedid MF, Pinto MA, Juchem JFG, Grezzana-Filho TJM, Kruel CRP. Liver preservation prior to transplantation: Past, present, and future. *World J Gastrointest Surg* 2019; 11(3): 122-125

**URL:** https://www.wjgnet.com/1948-9366/full/v11/i3/122.htm

**DOI:** https://dx.doi.org/10.4240/wjgs.v11.i3.122

**BACKGROUND**

Beginning in 1963, Dr. Thomas E. Starzl performed the first series of successful liver transplants (LTs) at the University of Colorado in Denver, United States[1].In the 1960s and 1970s, the results of LT were dismal with only a few transplants performed worldwide. Immunologic impairments were major barriers to the long-term success of LT until 1979, when Sir. Roy Calne, a British surgeon largely involved in the establishment of the concept of brain death, pioneered the use of cyclosporine in kidney, pancreas, and LTs[2-4].

Liver preservation was also a barrier to the progress of LT until the late 1980s. In 1988, Belzer’s group reported a successful LT using the University of Wisconsin preservation solution (UW)[5]. UW has replaced EuroCollins solution and allowed prolonged cold ischemia time and safer preservation of liver, kidney, and pancreas allografts, thus contributing to the improvement of transplant outcomes.

**CURRENT LIVER PRESERVATION TECHNIQUES**

Although UW is still considered the standard of care for organ preservation in the United States and in several countries worldwide, Adam *et al*[6] have recently reported similar LT outcomes using the Institut Georges Lopez-1 preservation solution (IGL-1) and UW. The study was a report from the European Liver Transplant Registry and compared the results of LT in relation to liver preservation using four different preservation solutions: UW, IGL-1, Celsior solution, and histidine-tryptophan-ketoglutarate preservation solution (HTK). The results of LT using UW and IGL-1 were slightly superior to those obtained with HTK, especially in the setting of prolonged cold ischemia time[6]. A recent meta-analysis also revealed similar post-transplant outcomes among liver allografts preserved with UW, Celsior, IGL-1, and HTK[7].Recently, in a series of 100 consecutive LTs using IGL-1, our group identified prolonged warm ischemia time as the only adverse prognostic factor for allograft survival[8].

In kidney transplant, IGL-1 has also produced results similar to those obtained with UW[9]. Our group also pioneered in the successful use of IGL-1 in human pancreas transplant[10].

Static cold storage has been the standard of care for graft preservation in liver, kidney, and pancreas transplants worldwide. High-risk lung allografts have been preserved dynamically (normothermic *ex-vivo* lung perfusion), with post-transplant outcomes similar to those of conventionally preserved lungs[11].Recently, dynamic preservation has also been used to preserve liver and kidney allografts. There are three different methods of dynamic preservation: normothermic machine perfusion (NMP), subnormothermic machine perfusion (SNMP), and hypothermic machine perfusion (HMP)[12,13].

Although associated with increased costs, NMP of liver allografts has been shown to be clinically feasible[14]. NMP can be performed *in situ* or *ex situ* and has been capable of improving laboratory perfusion parameters of marginal organs[13,14]. In a recent randomized trial, normothermic preservation was associated with both a 50% lower level of graft injury and a 50% lower rate of organ discard compared with static cold storage[15]. No difference was observed in bile duct complications, patient survival, or graft survival between the two groups.

SNMP is a strategy aiming to allow the use of extended criteria donor organs. It is usually performed at temperatures around 20℃. During perfusion, liver function restoration is reflected in urea, albumin, and bile production, with a tendency to improve post-ischemia parameters[16].The use of SNMP has the advantage of mitigating ischemia-reperfusion injury (IRI)[17], maintaining liver metabolism and allowing assessment of organ function prior to LT.

HMP is the most widely investigated of the three techniques, with promising results. In LT, the results for organs from donation after cardiac death (DCD) preserved with HMP have been similar to those of standard donation after brain death (DBD) organs[17]. Technical variants, such as dual vessel HMP (hepatic artery and portal vein perfusion), may potentially lead to additional outcome improvements.

**FUTURE PERSPECTIVES**

LT with the use of DCD donor livers, also known as non-heart beating donor livers, is a strategy to face organ shortage. The use of liver allografts procured from DCD donors has contributed to a considerable increase in the donor pool in the United States and in some European countries. LT using DCD livers has provided results that are nearly as good as those obtained with the use of DBD livers[18,19]. However, the occurrence of ischemic-type biliary lesions (ITBL) is a major concern when using DCD livers. The use of DCD organs increases the incidence of ITBL from 1%-3% to 10%-30%[19]. HMP has been reported to reduce the occurrence of ITBL[17], what is crucial to improve clinical outcomes, since 50% of patients with ITBL require retransplantation or die.

**CONCLUSION**

Machine perfusion techniques are recent advances, and there is a possibility of combining them or improving them to achieve better results. The ideal perfusion temperature, the possible benefits of adding pharmacological interventions to mitigate reperfusion injury, and the impact of minor technical refinements, such as dual hypothermic oxygenated perfusion, still need to be defined.

#### REFERENCES

1 **Starzl TE**, Marchioro TL, Vonkaulla KN, Hermann G, Brittain RS, Waddell WR. Homotransplantation Of The Liver In Humans. *Surg Gynecol Obstet* 1963; **117**: 659-676 [PMID: 14100514]

2 **Calne RY**, Rolles K, White DJ, Thiru S, Evans DB, McMaster P, Dunn DC, Craddock GN, Henderson RG, Aziz S, Lewis P. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. *Lancet* 1979; **2**: 1033-1036 [PMID: 91781 DOI: 10.1016/S0140-6736(79)92440-1]

3 **Starzl TE**, Klintmalm GB, Porter KA, Iwatsuki S, Schröter GP. Liver transplantation with use of cyclosporin a and prednisone. *N Engl J Med* 1981; **305**: 266-269 [PMID: 7017414]

4 **Iwatsuki S**, Starzl TE, Todo S, Gordon RD, Esquivel CO, Tzakis AG, Makowka L, Marsh JW, Koneru B, Stieber A. Experience in 1,000 liver transplants under cyclosporine-steroid therapy: a survival report. *Transplant Proc* 1988; **20**: 498-504 [PMID: 3279643]

5 **Kalayoglu M**, Sollinger HW, Stratta RJ, D'Alessandro AM, Hoffmann RM, Pirsch JD, Belzer FO. Extended preservation of the liver for clinical transplantation. *Lancet* 1988; **1**: 617-619 [PMID: 2894550]

6 **Adam R**, Delvart V, Karam V, Ducerf C, Navarro F, Letoublon C, Belghiti J, Pezet D, Castaing D, Le Treut YP, Gugenheim J, Bachellier P, Pirenne J, Muiesan P; ELTR contributing centres, the European Liver, Intestine Transplant Association (ELITA). Compared efficacy of preservation solutions in liver transplantation: a long-term graft outcome study from the European Liver Transplant Registry. *Am J Transplant* 2015; **15**: 395-406 [PMID: 25612492 DOI: 10.1111/ajt.13060]

7 **Szilágyi ÁL**, Mátrai P, Hegyi P, Tuboly E, Pécz D, Garami A, Solymár M, Pétervári E, Balaskó M, Veres G, Czopf L, Wobbe B, Szabó D, Wagner J, Hartmann P. Compared efficacy of preservation solutions on the outcome of liver transplantation: Meta-analysis. *World J Gastroenterol* 2018; **24**: 1812-1824 [PMID: 29713134 DOI: 10.3748/wjg.v24.i16.1812]

8 **Chedid MF**, Bosi HR, Chedid AD, Alvares-da-Silva MR, Leipnitz I, Grezzana-Filho TJM, Reis MJ, Filho GM, Ghissi AJ, Neto PR, de Araujo A, Arruda S, Lopes AB, Michalczuk MT, Backes AN, Kruel CDP, Kruel CRP. One Hundred Consecutive Liver Transplants Using Institutes Georges Lopez-1 Preservation Solution: Outcomes and Prognostic Factors. *Transplant Proc* 2017; **49**: 848-851 [PMID: 28457409 DOI: 10.1016/j.transproceed.2017.01.061]

9 **Codas R**, Petruzzo P, Morelon E, Lefrançois N, Danjou F, Berthillot C, Contu P, Espa M, Martin X, Badet L. IGL-1 solution in kidney transplantation: first multi-center study. *Clin Transplant* 2009; **23**: 337-342 [PMID: 19210685 DOI: 10.1111/j.1399-0012.2009.00959.x]

10 **Chedid MF**, Grezzana-Filho TJ, Montenegro RM, Leipnitz I, Hadi RA, Chedid AD, Kruel CR, Ribeiro AR, Gressler JB, Denicol NT, Kruel CD, Manfro RC. First Report of Human Pancreas Transplantation Using IGL-1 Preservation Solution: A Case Series. *Transplantation* 2016; **100**: e46-e47 [PMID: 27163542 DOI: 10.1097/TP.0000000000001242]

11 **Cypel M**, Yeung JC, Liu M, Anraku M, Chen F, Karolak W, Sato M, Laratta J, Azad S, Madonik M, Chow CW, Chaparro C, Hutcheon M, Singer LG, Slutsky AS, Yasufuku K, de Perrot M, Pierre AF, Waddell TK, Keshavjee S. Normothermic ex vivo lung perfusion in clinical lung transplantation. *N Engl J Med* 2011; **364**: 1431-1440 [PMID: 21488765 DOI: 10.1056/NEJMoa1014597]

12 **Quillin RC 3rd**, Guarrera JV. Hypothermic machine perfusion in liver transplantation. *Liver Transpl* 2018; **24**: 276-281 [PMID: 29278454 DOI: 10.1002/lt.25004]

13 **Ravikumar R**, Jassem W, Mergental H, Heaton N, Mirza D, Perera MT, Quaglia A, Holroyd D, Vogel T, Coussios CC, Friend PJ. Liver Transplantation After Ex Vivo Normothermic Machine Preservation: A Phase 1 (First-in-Man) Clinical Trial. *Am J Transplant* 2016; **16**: 1779-1787 [PMID: 26752191 DOI: 10.1111/ajt.13708]

14 **Angelico R**, Perera MT, Ravikumar R, Holroyd D, Coussios C, Mergental H, Isaac JR, Iqbal A, Cilliers H, Muiesan P, Friend PJ, Mirza DF. Normothermic Machine Perfusion of Deceased Donor Liver Grafts Is Associated With Improved Postreperfusion Hemodynamics. *Transplant Direct* 2016; **2**: e97 [PMID: 27795989 DOI: 10.1097/TXD.0000000000000611]

15 **Nasralla D**, Coussios CC, Mergental H, Akhtar MZ, Butler AJ, Ceresa CDL, Chiocchia V, Dutton SJ, García-Valdecasas JC, Heaton N, Imber C, Jassem W, Jochmans I, Karani J, Knight SR, Kocabayoglu P, Malagò M, Mirza D, Morris PJ, Pallan A, Paul A, Pavel M, Perera MTPR, Pirenne J, Ravikumar R, Russell L, Upponi S, Watson CJE, Weissenbacher A, Ploeg RJ, Friend PJ; Consortium for Organ Preservation in Europe. A randomized trial of normothermic preservation in liver transplantation. *Nature* 2018; **557**: 50-56 [PMID: 29670285 DOI: 10.1038/s41586-018-0047-9]

16 **Schlegel A**, Muller X, Kalisvaart M, Muellhaupt B, Perera MTPR, Isaac JR, Clavien PA, Muiesan P, Dutkowski P. Outcomes of DCD liver transplantation using organs treated by hypothermic oxygenated perfusion before implantation. *J Hepatol* 2019; **70**: 50-57 [PMID: 30342115 DOI: 10.1016/j.jhep.2018.10.005]

17 **Boteon YL**, Boteon AP, Attard J, Wallace L, Bhogal RH, Afford SC. Impact of machine perfusion of the liver on post-transplant biliary complications: A systematic review. *World J Transplant* 2018; **8**: 220-231 [PMID: 30370232 DOI: 10.5500/wjt.v8.i6.220]

18 **Buis CI**, Hoekstra H, Verdonk RC, Porte RJ. Causes and consequences of ischemic-type biliary lesions after liver transplantation. *J Hepatobiliary Pancreat Surg* 2006; **13**: 517-524 [PMID: 17139425 DOI: 10.1007/s00534-005-1080-2]

19 **Croome KP**, Lee DD, Perry DK, Burns JM, Nguyen JH, Keaveny AP, Taner CB. Comparison of longterm outcomes and quality of life in recipients of donation after cardiac death liver grafts with a propensity-matched cohort. *Liver Transpl* 2017; **23**: 342-351 [PMID: 28027600 DOI: 10.1002/lt.24713]

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** Brazil

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Mikulic D, Ramsay MA **S-Editor:** Dou Y **L-Editor:** A **E-Editor:** Zhang YL